key: cord-0741133-er3y5590
authors: Jérôme, Barrière; Emmanuel, Chamorey; Zoubir, Adjtoutah; Olivier, Castelnau; Abakar, Mahamat; Sabine, Marco; Emmanuel, Petit; Axel, Leysalle; Vincent, Raimondi; Michel, Carles
title: Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors.
date: 2021-04-28
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.04.019
sha: 9b4bb3a5100eec506585604deedf3cd60d4fe595
doc_id: 741133
cord_uid: er3y5590

nan

Patients in the active phase of treatment for cancer is a population at risk of COVID-19 with poor prognosis (1) . While a majority of patients treated for cancer expressed their will to be vaccinated as early as December 2020 in a French survey (2) , no data was available in terms of vaccine efficacy and tolerance, because they were excluded from initial registration trials. i.e.,without known ongoing cancer was also formed and vaccinated during the same period.

Serological assays were realized at week (w) 0 during the first vaccination, during the booster 

Analyses of Risk, Racial Disparity, and Outcomes Among US Patients with Cancer and COVID-19 Infection

Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a crosssectional survey

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

We acknowledge the following individuals for their assistance with this